消化器的选择性排毒揭示了冷压果分量如何调节脑间葡萄糖运输,并刺激GLP-1分泌
Ivan M Lopez-Rodulfo1, Martin K Rasmussen1, Bruce Hamaker2
1Centre for Innovative Food (CiFOOD), Department of Food Science, Aarhus University, Agro Food Park 48, Aarhus N 8200, Denmark.
Food chemistry
|March 3, 2026
概括
果和果末可以抑制葡萄糖的运输. 马的消化显著增强了类似葡萄糖-1 (GLP-1) 的分泌,这表明对血糖控制和食欲调节有好处.
科学领域:
- 营养科学 营养科学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 饮食中的多醇会影响葡萄糖代谢和荷尔蒙分泌.
- 对于营养科学来说,了解果和果消化的生理影响至关重要.
研究的目的:
- 在体外研究整个果和果残渣对葡萄糖运输和GLP-1分泌的影响.
- 在模拟的胃和肠道消化器中分析多的分布和活性.
主要方法:
- 开发了一种实验室方法来模拟消化,在没有细胞毒性的情况下将多醇度翻一番.
- 用Caco-2细胞单层化净化消化剂和使用UHPLC-ESI-QTOF-MS/MS分析的多醇含量.
- 评估葡萄糖运输和GLP-1分泌物,以应对果和果的消化.
主要成果:
- 果和麦片抑制了体内葡萄糖的运输,主要是由于二甲基和基酸.
- 果和果汁的胃消化剂增加了50%的GLP-1分泌.
- Pomace digesta在肠道消化后显著增加GLP-1分泌 (179%和62%的增加).
结论:
- 果和果的多醇调节葡萄糖的运输和GLP-1的分泌.
- 果果显示出减轻食后血糖和调节食欲的潜力,这是由于持续释放GLP-1导致的.
相关概念视频
Transcellular Transport of Solutes
4.0K
Transcellular transport of solutes is the movement of substances like monosaccharides and amino acids through polarized cells. This transport mechanism is primarily seen in epithelial and endothelial cells aided by membrane transport proteins such as channels and transporters. The tight junctions between these cells confine the membrane proteins to the two sides of the cell. The epithelial cells have distinct apical and basolateral domains. In contrast, the endothelial cells show the luminal...
4.0K
Glucose Transporters
15.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.2K
Glucose Absorption Into the Small Intestine
34.0K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.0K
Carbohydrate Absorption
12.8K
Carbohydrates are essential macronutrients that serve as the body's primary energy source. Their digestion begins in the mouth, where salivary amylase partially breaks down complex carbohydrates such as starch into smaller oligosaccharides. This mechanical and enzymatic activity prepares carbohydrates for further processing in the gastrointestinal tract.
After being swallowed, the partially digested carbohydrates mix with gastric secretions in the stomach. However, the acidic environment...
After being swallowed, the partially digested carbohydrates mix with gastric secretions in the stomach. However, the acidic environment...
12.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K


